

ASX Announcement



Medibio Limited – 1 October 2018

Notice Received Under Section 249D of the Corporations Act

Melbourne, Australia and Minneapolis, MN USA – 1 October 2018: The Board of Medibio Limited (**MEB or the Company**)(**ASX: MEB**)(**OTCQB: MDBIF**), advises that on 28 September 2018 it received a notice under Section 249D of the Corporations Act 2001 (**Section 249D Notice**) requesting the Company call and arrange to hold a meeting of the members of the Company.

The Section 249D Notice was received from:

- Carakho Holdings Pty Ltd
- SEK Investments Limited
- Bejjol Pty Limited
- Mining Investments Limited
- Gun Capital Management Pty Ltd
- Joshua Khouri
- Benjamin Khouri
- Peta Slocombe

who claim to hold approximately 6.29% of the issued capital of the Company. The Section 249D Notice seeks the removal of Mr Chris Indermaur and Mr Andrew Maxwell as Directors of the Company and the appointment of Mr Benjamin Richardson, Ms Peta Slocombe and Mr Elias Khouri as Directors of the Company.

The Company is seeking legal advice as the validity of the Section 249D Notice and will keep the market informed of all material developments concerning the requisition.

- ENDS -

Further Information:

Melanie Leydin
Company Secretary
Medibio Limited
mleydin@leydinfreyer.com.au
T: +61 3 9692 7222

About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices now located in Melbourne (Vic), Perth (WA) and Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.